Market Access
Navigating the Payer Landscape for Digital Therapeutics
Over the last several years, significant investments in digital health and technology solutions have ...
How Competition Affects Market Access for Rare Disease Therapeutics
For years, the rare disease community has looked forward to a time when patients ...
Impact of COVID-19 Pandemic on Funding and Reimbursement of Pharmaceuticals and Vaccines
Most European countries have experienced more than one wave of COVID-19 infections. Lockdown and ...
Communicating Value in a Golden Age of Vaccines
COVID-19 has given the world a crash course in virology and vaccines. PPE, N95, ...
Busting Cell and Gene Therapy Myths to Banish Patient, Provider, and Payer Concerns
Cell and gene therapies (CGTs) have the potential to transform healthcare for patients suffering from a wide ...
5 Essential Steps to Address Access Barriers Beyond Coverage
For years, payer strategies in the U.S. have had just one goal in mind: ...
How COVID-19 Has Changed the Way We Reach Payers
We still don’t know how COVID-19 will affect us over time, but details are ...
Into the Mind of the Payer
Payers (Aetna, BCBS, Humana, etc.) are very aware of the power they hold over ...
How Do You Define Value in Healthcare?
One the biggest questions in the cancer care ecosystem is: When can we expect ...
How Will Politics, Economic Stress, COVID, and More Change the Payer Landscape?
To help get at the heart of how the events of the past year ...
Successfully Navigating the Long Road to Medical Device Reimbursement
The Road to Hana is a 64-mile stretch of highway connecting Kahului to the ...
Three Areas Payers Are Redefining Following COVID
The pandemic has altered every facet of our healthcare system, so the payer landscape ...
Two Key Questions About Payer Strategies in 2021
PM360 asked experts in market access and working with payers what innovations to expect ...
